NervGen Pharma (NGEN)
Develops NVG-291 for spinal-cord injury.
$2.01
vs last close−0.06 (−2.66%)
Something off on this page? Send us feedback.
Next report
Nov 12, 26
estimated · in 50 days
EPS estimate
−$0.10
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Apr '25May '25Aug '25Nov '25Apr '26May '26Aug '26Nov '26
Reported−$0.10−$0.04−$0.09−$0.04−$0.26−$0.01−$0.37Pending
Estimate−$0.06−$0.06−$0.05−$0.06−$0.06−$0.07−$0.06−$0.10
Surprise−68.4%+30.0%−71.7%+30.0%−304.6%+80.4%−510.8%—
RevenueReportedEstimate
Apr '25May '25Aug '25Nov '25Apr '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————$4.5K$4.5K$4.5K—
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.10 | — | — |
| Sep 2027 | −$0.11 | — | — |
| Jun 2027 | −$0.10 | — | — |
| Mar 2027 | −$0.09 | — | — |
| Dec 2026 | −$0.09 | — | — |
| Nov 2026 | −$0.10 | — | — |
| Aug 2026 | −$0.06 | −$0.37 | −510.8% |
| May 2026 | −$0.07 | −$0.01 | +80.4% |
| Apr 2026 | −$0.06 | −$0.26 | −304.6% |
| Nov 2025 | −$0.06 | −$0.04 | +30.0% |
| Aug 2025 | |||
| May 2025 | |||
| Apr 2025 | |||
| Nov 2024 | |||
| May 2024 | |||
| Apr 2024 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.10 | — | — | $0 | — | — | — |
| Sep 2027 | −$0.11 | — | — | $0 | — | — | — |
| Jun 2027 | −$0.10 | — | — | $0 | — | — | — |
| Mar 2027 | −$0.09 | — | — | $0 | — | — | — |
| Dec 2026 | −$0.09 | — | — | $0 | — | — | — |
| Nov 12, 2026 | −$0.10 | — | — | $0 | — | — | — |
| Aug 13, 2026 | −$0.06 | −$0.37 | −510.8% | $4.5K | — | — | 0.0% |
| May 18, 2026 | −$0.07 | −$0.01 | +80.4% | $4.5K | — | — | +2.0% |
| Apr 2, 2026 | −$0.06 | −$0.26 | −304.6% | $4.5K | — | — | −2.3% |
| Nov 25, 2025 | −$0.06 | −$0.04 | +30.0% | — | — | — | — |
| Aug 27, 2025 | |||||||
| May 15, 2025 | |||||||
| Apr 3, 2025 | |||||||
| Nov 14, 2024 | |||||||
| May 16, 2024 | |||||||
| Apr 16, 2024 |